Business Context and Reporting Period
This Form 8-K Current Report was filed by MaxCyte, Inc. on October 14, 2024. The filing reports a corporate governance event: the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Board Expansion: The Board of Directors increased in size from nine to ten members.
- New Appointment: Cynthia Collins was appointed as a Class II director, effective October 14, 2024.
- Committee Assignment: Ms. Collins was appointed to the Compensation Committee.
Compensation and Equity Grants
In connection with her appointment, Ms. Collins received the following equity awards, subject to continued service:
- Stock Options: 97,698 options vesting over three years (one-third after 12 months, remainder ratably monthly).
- Restricted Stock Units (RSUs): 51,679 RSUs vesting 100% after 12 months.
- Settlement: Both awards are settled in shares of the Company's common stock.
Outlook, Risks, and Management Commentary
The filing states there are no arrangements or understandings regarding Ms. Collins' selection other than standard director compensation and indemnification. A press release detailing the appointment was issued on October 15, 2024. No specific risks, contingencies, or forward-looking guidance regarding business operations are provided in this report.
Investor Verification Checklist
- Verify the total number of directors on the Board is now ten.
- Confirm the vesting schedule details for the 97,698 stock options and 51,679 RSUs granted to Cynthia Collins.
- Review the Company's Definitive Proxy Statement (Schedule 14A) filed on April 26, 2024, for the full director compensation program details.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.